Potential of liraglutide in the treatment of patients with type 2 diabetes

References

• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapyDiabetes Care20093219320318945920
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet19983528548659742977
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med20063552427244317145742
   PubMed Web of Science ®Google Scholar
• BaggioLLDruckerDJBiology of incretins: GLP-1 and GIPGastroenterology20071322131215717498508
   PubMed Web of Science ®Google Scholar
• HolstJJThe physiology of glucagon-like peptide 1Physiol Rev2007871409143917928588
   PubMed Web of Science ®Google Scholar
• HolstJJVilsbøllTDeaconCFThe incretin system and its role in type 2 diabetes mellitusMol Cell Endocrinol200929712713618786605
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCHolstJJWillmsBCreutzfeldtWNormalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia1993367417448405741
   PubMed Web of Science ®Google Scholar
• RachmanJBarrowBALevyJCTurnerRCNear-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDMDiabetologia1997402052119049482
   PubMed Web of Science ®Google Scholar
• ZanderMMadsbadSMadsenJLHolstJJEffect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group studyLancet200235982483011897280
   PubMed Web of Science ®Google Scholar
• DeaconCFNauckMAToft-NielsenMPridalLWillmsBHolstJJBoth subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjectsDiabetes199544112611317657039
   PubMed Web of Science ®Google Scholar
• DeaconCFPridalLKlarskovLOlesenMHolstJJGlucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pigAm J Physiol1996271E458E4648843738
   PubMed Web of Science ®Google Scholar
• VilsbøllTAgersøHKrarupTHolstJJSimilar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjectsJ Clin Endocrinol Metab20038822022412519856
   PubMed Web of Science ®Google Scholar
• PlamboeckAHolstJJCarrRDDeaconCFNeutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pigDiabetologia20054891882189016025254
   PubMed Web of Science ®Google Scholar
• SimonsenLHolstJJDeaconCFExendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigsDiabetologia20064970671216447056
   PubMed Web of Science ®Google Scholar
• DeaconCFKnudsenLBMadsenKWibergFCJacobsenOHolstJJDipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activityDiabetologia1998412712789541166
   PubMed Web of Science ®Google Scholar
• ChenYEDruckerDJTissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizardJ Biol Chem1997272410841159020121
   PubMed Web of Science ®Google Scholar
• KnudsenLBNielsenPFHuusfeldtPOPotent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administrationJ Med Chem2000431664166910794683
   PubMed Web of Science ®Google Scholar
• AgersøHJensenLBElbrøndBRolanPZdravkovicMThe pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy menDiabetologia20024519520211935150
   PubMed Web of Science ®Google Scholar
• BjornsdottirIOlsenALarsenUMetabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidaseDiabetologia200851Suppl 1S356(abstract).
   Google Scholar
• JacobsenLVHindsbergerCRobsonRZdravkovivMPharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairmentDiabetes200756Suppl 1A137(abstract).
   PubMedGoogle Scholar
• DamholtBGolorGWierichWPedersenPEkblomMZdravkovicMAn open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutideJ Clin Pharmacol20064663564116707410
   PubMed Web of Science ®Google Scholar
• IrieSMatsumuraYZdravkovicMJacobsenLVKageyamaSTolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation studyInt J Clin Pharmacol Ther20084627327918541123
   PubMed Web of Science ®Google Scholar
• JuhlCBHollingdalMSturisJBedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetesDiabetes20025142442911812750
   PubMed Web of Science ®Google Scholar
• DegnKBJuhlCBSturisJOne week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetesDiabetes2004531187119415111485
   PubMed Web of Science ®Google Scholar
• HarderHNielsenLTuDTAstrupAThe effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetesDiabetes Care2004271915192115277417
   PubMed Web of Science ®Google Scholar
• MadsbadSSchmitzORanstamJJakobsenGMatthewsDRImproved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trialDiabetes Care2004271335134215161785
   PubMed Web of Science ®Google Scholar
• FeinglosMNSaadMFPi-SunyerFXAnBSantiagoOEffects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetesDiabet Med2005221016102316026367
   PubMed Web of Science ®Google Scholar
• NauckMAHompeschMFilipczakRLeTDZdravkovicMGumprechtJFive weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetesExp Clin Endocrinol Diabetes200611441742317039422
   PubMed Web of Science ®Google Scholar
• VilsbøllTZdravkovicMLe-ThiTLiraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetesDiabetes Care2007301608161017372153
   PubMed Web of Science ®Google Scholar
• SeinoYRasmussenMFZdravkovicMKakuKDose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetesDiabetes Res Clin Pract20088116116818495285
   PubMed Web of Science ®Google Scholar
• MatsumotoKMiyakeSYanoMGlucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjectsDiabetes Care199720156215689314636
   PubMed Web of Science ®Google Scholar
• MarreMShawJBrandleMLiraglutide, a once daily human GLP-1 analog, added to a sulphoflurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetesDiabetes200857Suppl 1A4(abstract).
   Google Scholar
• MarreMShawJBrandleMLiraglutide added to a sulphonylurea (SU) offers significantly better glycaemic control and favourable weight change compared with rosiglitazone and SU combination therapy in T2DMDiabetologia200851Suppl 1S359(abstract).
   Google Scholar
• NauckMFridAHermansenKEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met)Diabetes Care200932849018931095
   PubMed Web of Science ®Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialLancet2008924[Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• ZinmanBGerichJBuseJEffect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomised double-blind placebo controlled trialDiabetologia200851Suppl 1S359(abstract).
   Google Scholar
• Russell-JonesDVaagASchmitzOSignificantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetesDiabetes200857Suppl 1A159(abstract).
   Google Scholar
• Russell-JonesDVaagASchmitzOSignificantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in type 2 diabetesDiabetologia200851Suppl 1S68(abstract).
   Google Scholar
• BlondeLRosenstockJSestiGLiraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes. 2008 CDA/CSEM Professional Conference and Annual Meetings, abstract 107. [accessed 3 December 2008]. Available from: http://www.diabetes.ca/files/for-professionals/conference-abstract-book.pdf
   Google Scholar
• Novo Nordisk [website]. 26th October 2008 Capital markets day: liraglutide [accessed 26 November 2008]. Available from: http://www.novonordisk.com/images/investors/capital-markets-day/2008/Liraglutide.pdf
   Google Scholar
• BregenholtSMøldrupABlumeNThe long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitroBiochem Biophys Res Commun200533057758415796922
   PubMed Web of Science ®Google Scholar
• FriedrichsenBNNeubauerNLeeYCStimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathwaysJ Endocrinol200618848149216522728
   PubMed Web of Science ®Google Scholar
• PrazakRRuttiSEllingsgaardHKnudsenLBDonathMLiraglutide induces cell proliferation and protects from interleukin-1 beta-induced β-cell apoptosis in human isletsDiabetologia200851Suppl 1S212(abstract).
   Google Scholar
• RolinBLarsenMOGotfredsenCFThe long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic miceAm J Physiol Endocrinol Metab2002283E745E75212217892
   PubMed Web of Science ®Google Scholar
• SturisJGotfredsenCFRømerJGLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamicsBr J Pharmacol200314012313212967942
   PubMed Web of Science ®Google Scholar
• ChangAMJakobsenGSturisJThe GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single doseDiabetes2003521786179112829647
   PubMed Web of Science ®Google Scholar
• VilsbøllTBrockBPerrildHLiraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitusDiabet Med20082515215618201212
   PubMed Web of Science ®Google Scholar
• MariADegnKBrockBRungbyJFerranniniESchmitzOEffects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditionsDiabetes Care2007302032203317468345
   PubMed Web of Science ®Google Scholar
• ColagiuriSFridAZradvkovicMLiraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetesDiabetologia200851Suppl 1S360(abstract).
   Google Scholar
• HorowitzMVilsbøllTZdravkovicMHammerMMadsbadSPatient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutideDiabetes Obes Metab20081059359618435773
   PubMed Web of Science ®Google Scholar
• NauckMAEl-OuaghlidiAHompeschMJacobsenJElbroendBNo impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2 diabetesDiabetes200352Suppl 1A128(abstract).
   Google Scholar
• HermansenKNauckMAFridALiraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced bodyweight compared with glimepiride when added to metformin (LEAD-2)Diabetologia200851Suppl 1S358(abstract).
   Google Scholar
• AhmadSRSwannJExenatide and rare adverse eventsN Engl J Med20083581970197118456920
   PubMed Web of Science ®Google Scholar
• BainSCStephensJWExenatide and pancreatitis: an updateExpert Opin Drug Saf2008764364418983211
   PubMed Web of Science ®Google Scholar
• ReutensATShawJEIncretin mimetics and enhancers: clinical applicationsAust Prescr200831104108
   Web of Science ®Google Scholar
• NoelRABraunDKPattersonREBloomgrenGIncreased risk of acute pancreatitis observed in patients with type 2 diabetesPancreas200837487(abstract).
   Web of Science ®Google Scholar
• BuseJBHenryRRHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care2004272628263515504997
   PubMed Web of Science ®Google Scholar
• KendallDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care2005281083109115855571
   PubMed Web of Science ®Google Scholar
• de HeerJHolstJJSulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1Diabetes20075643844317259389
   PubMed Web of Science ®Google Scholar
• HorowitzMFlintADoranSEffects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetesDiabetologia200851Suppl 1S355(abstract).
   Google Scholar
• FlintAKaptizaCHindsbergerCZdravkovicMThe once daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intakeDiabetes200857Suppl 1A165(abstract).
   Google Scholar
• BoseAKMocanuMMCarrRDBrandCLYellonDMGlucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injuryDiabetes20055414615115616022
   PubMed Web of Science ®Google Scholar
• BosiEByiersSRCohenSEVildagliptin significantly decreases blood pressure (BP) in hypertensive patients (pts) with type 2 diabetes (T2DM) compared with metforminDiabetes200756Suppl 1A139(abstract).
   Google Scholar
• MistryGCMaesALLasseterKCEffect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertensionJ Clin Pharmacol20084859259818353996
   PubMed Web of Science ®Google Scholar
• JendleJNauckMAMatthewsDRThe reduction in bodyweight with liraglutide, a once-daily human GLP-1 analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fatDiabetologia200851Suppl 1S318(abstract).
   Google Scholar
• FlintAKapitzaCHindsbergerCZdravkovicMThe once-daily human GLP-1 analogue liraglutide improves both absolute- and baseline-corrected postprandial glucose levelsDiabetologia200851Suppl 1S354(abstract).
   Google Scholar
• LinnebjergHParkSKotharePAEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetesRegul Pept200815112312918675854
   PubMedGoogle Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet20083721240125018782641
   PubMed Web of Science ®Google Scholar
• NauckMASauerwaldARitzelRHolstJJSchmiegelWInfluence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failureDiabetes Care199821192519319802745
   PubMed Web of Science ®Google Scholar
• NauckMAWollschlägerDWernerJEffects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDMDiabetologia199639154615538960841
   PubMed Web of Science ®Google Scholar
• LarsenJHyllebergBNgKDamsboPGlucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatmentDiabetes Care2001241416142111473079
   PubMed Web of Science ®Google Scholar
• KlonoffDCBuseJBNielsenLLExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurr Med Res Opin20082427528618053320
   PubMed Web of Science ®Google Scholar
• JonkerDMWatsonEToftADKristensenPKnudsenLBIngwersenSHPharmacokinetic modelling of the once-daily human glucagon.like peptide-1 analogue, liraglutide, in healthy volunteers and comparison to exenatideDiabetologia200750Suppl 1S351(abstract).
   Google Scholar
• HermanGABergmanAStevensCEffect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetesJ Clin Endocrinol Metab2006914612461916912128
   PubMed Web of Science ®Google Scholar
• HjollundKRHughesTEDeaconCFHolstJJThe dipeptidyl peptidase-4 inhibitor vildagliptin increases portal concentrations of active GLP-1 to a greater extent than the peripheral concentrationsDiabetes200857Suppl 1A411(abstract).
   Google Scholar
• HolstJJDeaconCFGlucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitorsDiabetologia20054861261515759106
   PubMed Web of Science ®Google Scholar
• GökeBHershonKKerrDEfficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metforminHorm Metab Res20084089289518726829
   PubMed Web of Science ®Google Scholar
• PratleyRESchweizerARosenstockJRobust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy databaseDiabetes Obes Metab20081093193818093207
   PubMed Web of Science ®Google Scholar
• XuLManCDCharbonnelBEffect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approachDiabetes Obes Metab2008101212122018476982
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerAdejagerSDunningBEPerssonMFoleyJEVildagliptin improves alpha cell glucose sensing in patients with type 2 diabetesDiabetologia200851Suppl 1S36(abstract).
   Google Scholar
• DeFronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellLEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over studyCurr Med Res Opin2008242943295218786299
   PubMed Web of Science ®Google Scholar
• Novo Nordisk [website]. Liraglutide press release, 16 June 2008 [accessed 3rd December 2008]. Available from: http://www.novonordisk.com/science/Pipeline/liraglutide-press-releases.asp
   Google Scholar